Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Nature Medicine 14, 469 (1 May 2008) | doi:10.1038/nm0508-469;
Return to the basics might breathe life into HIV vaccine pipeline
Abstract
As the financial world grapples with major market corrections, the HIV research community faces its own reality check. The scientific reassessment comes after disappointing results from a candidate HIV vaccine developed by Merck caused the company to halt human trials of the potential vaccine last September.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).